BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pilon D, Ding Z, Muser E, Obando C, Voelker J, Manceur AM, Kinkead F, Lafeuille MH, Lefebvre P. Long-term direct and indirect costs of ulcerative colitis in a privately-insured United States population. Curr Med Res Opin 2020;36:1285-94. [PMID: 32427006 DOI: 10.1080/03007995.2020.1771293] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Mittal M, Yang M, Shah M, Gao W, Carley C, Sherman BW. Impact of Medication Adherence on Healthcare Resource Utilization, Work Loss, and Associated Costs in a Privately Insured Employed Population Treated With Adalimumab in the United States. J Occup Environ Med 2021;63:e724-31. [PMID: 34412091 DOI: 10.1097/JOM.0000000000002354] [Reference Citation Analysis]
2 Miyazaki C, Katsumasa N, Huang KC, Liu YF. Evaluation of economic burden with biologic treatments in Crohn's disease patients: A mirror image study using an insurance database in Japan. PLoS One 2021;16:e0254807. [PMID: 34280242 DOI: 10.1371/journal.pone.0254807] [Reference Citation Analysis]
3 Sieluk J, Song Y, Freimark J, Huang M, Haiderali A, Berman R, Wang T, Signorovitch J, Hirshfield KM. The Economic Burden of Recurrence in Triple-Negative Breast Cancer Among Working Age Patients in the United States. Adv Ther 2022;39:943-58. [PMID: 34918193 DOI: 10.1007/s12325-021-01913-5] [Reference Citation Analysis]
4 van Linschoten RCA, Visser E, Niehot CD, van der Woude CJ, Hazelzet JA, van Noord D, West RL. Systematic review: societal cost of illness of inflammatory bowel disease is increasing due to biologics and varies between continents. Aliment Pharmacol Ther 2021;54:234-48. [PMID: 34114667 DOI: 10.1111/apt.16445] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]